DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Climara PRO (Estradiol / Levonorgestrel Transdermal) - Published Studies


Climara PRO Related Published Studies

Well-designed clinical trials related to Climara PRO (Estradiol / Levonorgestrel)

Simultaneous estradiol and levonorgestrel transdermal delivery from a 7-day patch: in vitro and in vivo drug deliveries of three formulations. [2007.04]

Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis. [2005.02.14]

A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel. [2005.02]

Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. [2005.02]

Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. [2004.06]

Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism. [2004.02]

An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 microg ethinylestradiol and 150 microg levonogestrel/30 microg ethinylestradiol in Thai women. [2004.01]

Clinical comparative study of oral contraceptives containing 30 microg ethinylestradiol/150 microg levonorgestrel, and 35 microg ethinylestradiol/250 microg norgestimate in Thai women. [2002.12]

The effect of extending the pill-free interval on follicular activity: triphasic norgestimate/35 micro g ethinyl estradiol versus monophasic levonorgestrel/20 micro g ethinyl estradiol. [2002.09]

Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial. [2002.09]

Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline. [2002.07]

Endometrial safety of a transdermal sequential estradiol-levonorgestrel combination. [2002.06]

Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. [2002.05]

Effect of two oral contraceptives containing ethinylestradiol and levonorgestrel on serum and urinary surrogate markers of endothelial function. [2002.04]

Efficacy of a new 7-day transdermal sequential estradiol/levonorgestrel patch in women. [2002.03.25]

Estradiol and levonorgestrel: effects on bleeding pattern when administered in a sequential combined regimen with a new transdermal patch. [2002.03]

An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. [2002.03]

Effect of two oral contraceptives with different ethinyl estradiol and levonorgestrel concentrations on the urinary excretion of biochemical vasoactive markers. [2001.12]

The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. [2001.11]

A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment. [2001.09]

Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size. [2001.07]

Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 microg ethinylestradiol/100 microg levonorgestrel and 20 microg ethinylestradiol/500 microg norethisterone. [2001.07]

A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 microg levonorgestrel with 20 microg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol. [1999.11]

A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 micrograms/20 micrograms versus triphasic norethindrone/ethinylestradiol 500-750-1000 micrograms/35 micrograms: a multicenter, randomized, open-label study. [1999.06]

Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. [1999.06]

Cycle control with oral contraceptives containing 20 micrograms of ethinyl estradiol. A multicenter, randomized comparison of levonorgestrel/ethinyl estradiol (100 micrograms/20 micrograms) and norethindrone/ethinyl estradiol (1000 micrograms/20 micrograms). [1999.03]

Short-term treatment with levonorgestrel does not antagonize the ethinyl estradiol-induced increase of uterine blood flow in postmenopausal women. [1997.09]

[Effect of ethinyl estradiol-dienogest combination on serum androgen concentrations] [1997]

A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response. [1996.11]

The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users. [1996.10]

Intrauterine or oral administration of levonorgestrel in combination with estradiol to perimenopausal women--effects on lipid metabolism during 12 months of treatment. [1996.09]

[Estrogenic effects after 14-days administration of 0.06 mg ethinyl estradiol in postmenopausal women] [1996.05]

Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. [1995.02]

Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. [1995]

Studies on a vaginal ring releasing levonorgestrel at an initial rate of 27 micrograms/24 h when used alone or in combination with transdermal systems releasing estradiol. [1994.07]

Sustained-release subdermal estradiol implants: a new alternative in estrogen replacement therapy. [1993.11]

Absence of an effect of high vitamin C dosage on the systemic availability of ethinyl estradiol in women using a combination oral contraceptive. [1993.10]

Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. [1992.11]

A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel. [1992.06]

Intrasubject variability in the pharmacokinetics of ethynyloestradiol. [1991.06]

A comparative study on the effects of a monophasic pill containing desogestrel plus 20 micrograms ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors. [1991.01]

A comparative study of the effects of a monophasic and a triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel on lipid and lipoprotein metabolism. [1990.11]

Pharmacokinetics and biotransformation of orally administered oestrone sulphate and oestradiol valerate in post-menopausal women. [1990.11]

Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. [1990.01]

Changes in lipoprotein composition in women receiving two low-dose oral contraceptives containing ethinylestradiol and gonane progestins. [1988.06]

Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration. [1987.10]

The relative bioavailability of levonorgestrel and ethinylestradiol when administered in tablet and capsule form. [1987.09]

Blood coagulation with a combination pill containing gestodene and ethinyl estradiol. [1987]

The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive. [1986.10]

Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel. [1985.04]

Comparison of contraceptive acceptability of levonorgestrel and ethinyl oestradiol administered in one three-phasic (Trionetta) and one monophasic (Neovletta) version. [1983.05]

A comparison of the pharmacokinetic properties of three estradiol esters. [1980.04]

Plasma lipids and high density lipoproteins during oral contraception with different combinations of ethinyl estradiol and levonorgestrel. [1979.07]

Well-designed clinical trials possibly related to Climara PRO (Estradiol / Levonorgestrel)

A trial of contraceptive methods in women with systemic lupus erythematosus. [2005.12.15]

Effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist on spermatogenesis and intratesticular steroid levels in normal men. [2005.10]

Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial. [2005.07]

Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide. [2005.05]

Progestins and estrogens and Alzheimer's disease. [2005.02]

A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms. [2005.01]

The effect on cartilage of different forms of application of postmenopausal estrogen therapy: comparison of oral and transdermal therapy. [2004.11]

Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. [2004.11]

Mifepristone versus the Yuzpe regimen (PC4) for emergency contraception. [2004.11]

Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study. [2004.11]

[Antagonist protocols: residual LH levels and the value of exogenous LH supplementation] [2004.10]

A comparative study on the effects of a contraceptive vaginal ring NuvaRing and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function. [2004.09]

Effect of four oral contraceptives on hemostatic parameters. [2004.08]

Concomitant administration of lumiracoxib and a triphasic oral contraceptive does not affect contraceptive activity or pharmacokinetic profile. [2004.06]

Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression. [2004.04]

Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. [2004.02.01]

Sex hormone--binding globulin--a surrogate marker for the prothrombotic effects of combined oral contraceptives. [2004.02]

Effect of hormonal emergency contraception on bleeding patterns. [2004.02]

A randomized controlled trial of hysterectomy or levonorgestrel-releasing intrauterine system in the treatment of menorrhagia-effect on FSH levels and menopausal symptoms. [2004.02]

Estrogen replacement therapy in combination with continuous intrauterine progestin administration reduces the amount of circulating oxidized LDL in postmenopausal women: dependence on the dose of progestin. [2004]

Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. [2003.10]

Continuous intrauterine compared with cyclic oral progestin administration in perimenopausal HRT. [2003.09.25]

Effects of long-term estrogen replacement therapy versus combined hormone replacement therapy on nitric oxide-dependent vasomotor function. [2003.09]

A multicenter, randomized study of an extended cycle oral contraceptive. [2003.08]

Advance supply of emergency contraception. effect on use and usual contraception--a randomized trial. [2003.07]

Modifying the Yuzpe regimen of emergency contraception: a multicenter randomized controlled trial. [2003.06]

Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric Study. [2003.06]

A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris. [2003.05]

Effect of four oral contraceptives on thyroid hormones, adrenal and blood pressure parameters. [2003.05]

Efficacy of second versus third generation oral contraceptives in the treatment of hirsutism. [2003.05]

Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. [2003.04]

The male contraceptive regimen of testosterone and levonorgestrel significantly increases lean mass in healthy young men in 4 weeks, but attenuates a decrease in fat mass induced by testosterone alone. [2003.03]

The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. [2003.03]

Vitamin D receptor gene polymorphism and bone metabolism during low-dose oral contraceptive use in young women. [2003.01]

Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. [2003.01]

Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. [2003.01]

Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism. [2002.12]

Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. [2002.12]

Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. [2002.11]

Effects of two oral contraceptives on plasma levels of nitric oxide, homocysteine, and lipid metabolism. [2002.09]

Emergency contraception. [2002.08.06]

Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation. [2002.07]

Cognitive effects of short-term manipulation of serum sex steroids in healthy young men. [2002.07]

Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. [2002.07]

Efficacy and safety of oral and transdermal hormonal replacement treatment containing levonorgestrel. [2002.06.25]

A randomised study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception. [2002.05]

Long-term effects of combined oral contraceptives on markers of endothelial function and lipids in healthy premenopausal women. [2002.03]

Effect of dienogest-containing oral contraceptives on lipid metabolism. [2002.03]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017